Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification

Hypertension

Volumn 35, Issue 2, 2000, Pages 539-543

  Ogden, Lorraine G ^a   He, Jiang ^a   Lydick, Eva ^b   Whelton, Paul K ^a  

^a TULANE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Blood pressure; Cardiovascular diseases; Mortality; Risk factors

Indexed keywords

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; HUMAN; HYPERTENSION; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0033982396     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.2.539     Document Type: Article

References (24)

1. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
2. American Heart Association. Economic cost of cardiovascular diseases. In: 1997 Heart and Stroke Statistical Update. Dallas, Tx: American Heart Association; 1997.
3. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
4. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951-957.
5. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
6. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: an overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138: S211-S219.
7. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
8. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.
9. Whelton PK, He J. Prevention trials of blood pressure reduction. In Hennekens C, Buring J, Furberg C, Manson JE, eds. Clinical Trials in Cardiovascular Disease. Philadelphia, Pa: Saunders; 1999:341-359.
10. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:1413-2446.
11. Miller HW. Plan and operation of the Health and Nutrition Examination Survey: United States, 1971-1973. Vital Health Stat 1. 1973;1(10a):1-46.
12. Engel A, Murphy RS, Maurer K, Collins E. Plan and operation of the HANES I Augmentation Survey of Adults 25-74 years: United States, 1974-1975. Vital Health Stat 1. 1978;(14):1-110.
13. Cohen BB, Barbano HE, Cox CS, Feldman JJ, Finucane FF, Kleinman JC, Madans JH. Plan and operation of the NHANES I Epidemiologic Followup Study, 1982-84. Vital Health Stat 1. 1987;(22):1-142.
14. Finucane FF, Freid VM, Madans JH, Cox CS, Kleinman JC, Rothwell ST, Barbano HE, Feldman JJ. Plan and operation of the NHANES I Epidemiologic Follow-up Study, 1986. Vital Health Stat 1. 1990;(25):1-154.
15. Cox CS, Rothwell ST, Madans JH, Finucane FF, Freid VM, Kleinman JC, Barbano HE, Feldman JJ. Plan and operation of the NHANES I Epidemiologic Follow-up Study, 1987. Vital Health Stat 1. 1992;(27):1-190.
16. Cox CS, Mussolino ME, Rothwell ST, Lane MA, Golden CD, Madans JH, Feldman JJ. Plan and operation of the NHANES I Epidemiologic Followup Study, 1992. Vital Health Stat 1. 1997;(35):1-231.
17. McLaughlin JK, Dietz MS, Mehl ES, Blot WJ. Reliability of surrogate information on cigarette smoking by type of informant. Am J Epidemiol. 1987;126:144-146.
18. Machlin SR, Kleinman JC, Madans JH. Validity of mortality analysis based on retrospective smoking information. Stat Med. 1989;8:997-1009.
19. Madans JH, Reuben CA, Rothwell ST, Eberhardt MS. Differences in morbidity measures and risk factor identification using multiple data sources: the case of coronary heart disease. Stat Med. 1995;14:643-653.
20. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
21. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
22. LaRosa JC, He J, Vupputuri S. Effect of statin drug treatment on risk of coronary heart disease: a meta-analysis of randomized, controlled trials. JAMA. In press.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
24. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.